Show simple item record

dc.contributor.author Boadu, Akwasi
dc.contributor.author Agoni, Clement
dc.contributor.author Karpoormath, Rajshekhar
dc.contributor.author Soliman, Mahmoud
dc.contributor.author Nlooto, Manimbulu
dc.date.accessioned 2024-10-24T06:39:36Z
dc.date.available 2024-10-24T06:39:36Z
dc.date.issued 2022
dc.identifier.uri http://hdl.handle.net/10386/4704
dc.description Journal article published in Scientific Reports | (2022) 12:10896 en_US
dc.description.abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a pneumonia-like disease with a pattern of acute respiratory symptoms, currently remains a significant public health concern causing tremendous human suffering. Although several approved vaccines exist, vaccine hesitancy, limited vaccine availability, high rate of viral mutation, and the absence of approved drugs account for the persistence of SARS-CoV-2 infections. The investigation of possibly repurposing of phytochemical compounds as therapeutic alternatives has gained momentum due to their reported affordability and minimal toxicity. This study investigated anti-viral phytochemical compounds from ethanolic leaf extracts of Spondias mombin L as potential inhibitor candidates against SARS-CoV-2. We identified Geraniin and 2-O-Cafeoyl-(+)-allohydroxycitric acid as potential SARS-CoV-2 inhibitor candidates targeting the SARS-CoV-2 RNA-dependent polymerase receptor-binding domain (RBD) of SARSCoV-2 viral S-protein and the 3C-like main protease (3CLpro). Geraniin exhibited binding free energy (ΔGbind) of − 25.87 kcal/mol and − 21.74 kcal/mol towards SARS-CoV-2 RNA-dependent polymerase and receptor-binding domain (RBD) of SARS-CoV-2 viral S-protein respectively, whereas 2-O-Cafeoyl(+)-allohydroxycitric acid exhibited a ΔGbind of − 32 kcal/mol towards 3CLpro. Molecular Dynamics simulations indicated a possible interference to the functioning of SARS-CoV-2 targets by the two identified inhibitors. However, further in vitro and in vivo evaluation of these potential SARS-CoV-2 therapeutic inhibitor candidates is needed. en_US
dc.format.extent 14 pages en_US
dc.language.iso en en_US
dc.publisher Scientifc Reports en_US
dc.relation.requires PDF en_US
dc.subject Antiviral phytochemicals en_US
dc.subject Leaf extracts en_US
dc.subject Spondias mombin (Linn) en_US
dc.subject SARSCOV‑2 inhibitors en_US
dc.subject Respiratory Syndrome en_US
dc.subject Pneumonia-like disease en_US
dc.subject SARS-CoV-2 infections en_US
dc.subject.lcsh COVID-19 (Disease) en_US
dc.subject.lcsh Respiratory distress syndrome en_US
dc.subject.lcsh Mombin en_US
dc.title Repurposing antiviral phytochemicals from the leaf extracts of Spondias mombin (Linn) towards the identifcation of potential SARSCOV‑2 inhibitors en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ULSpace


Browse

My Account